NCT02130869: A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas |
|
|
| Completed | 1 | 8 | US | CD133+ selected autologous stem cell infusion, Natural killer (NK) cell infusion, IL-2, Interleukin-2, Aldesleukin, Proleukin(R), hu14.18K322A, anti-GD2 antibody, Hu14.18K322MAB, Busulfan, Busulfex(R), Myleran(R), Melphalan, L-phenylalanine mustard, Phenylalanine mustard, L-PAM, L-sarcolysin, GM-CSF, Sargramostim, Leukine(R), Bendamustine, Treanda®, Bendamustine hydrochloride, Etoposide, VP-16, Vepesid(R), Cytarabine, ARA-C, Carboplatin, Inorganic heavy metal coordination complex, Haploidentical natural killer cell infusion, NK cell infusion, G-CSF, Filgrastim, Neupogen(R), Etoposide phosphate, Etopophos(R), CliniMACS, Cell Selection System | St. Jude Children's Research Hospital | Neuroblastoma, Lymphoma, High-risk Tumor | 12/17 | 12/17 | | |
